Artiva Biotherapeutics, Inc.
ARTV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $662 | $0 | $0 | $0 |
| Gross Profit | -$662 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $16,971 | $17,861 | $17,052 | $13,317 |
| G&A Expenses | $0 | $4,949 | $5,119 | $4,950 |
| SG&A Expenses | $5,264 | $4,949 | $5,119 | $4,950 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $22,235 | $22,810 | $22,171 | $18,267 |
| Operating Income | -$22,897 | -$22,810 | -$22,171 | -$18,267 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,369 | $1,556 | $1,860 | $9,052 |
| Pre-Tax Income | -$21,528 | -$21,254 | -$20,311 | -$9,215 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$21,528 | -$21,254 | -$20,311 | -$9,215 |
| % Margin | – | – | – | – |
| EPS | -0.88 | -0.87 | -0.83 | -0.82 |
| % Growth | -1.1% | -4.8% | -1.2% | – |
| EPS Diluted | -0.88 | -0.87 | -0.83 | -0.82 |
| Weighted Avg Shares Out | 24,482 | 24,379 | 24,342 | 24,363 |
| Weighted Avg Shares Out Dil | 24,482 | 24,379 | 24,342 | 24,363 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,372 | $1,561 | $1,864 | $2,177 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $662 | $641 | $628 | $614 |
| EBITDA | -$20,866 | -$22,169 | -$21,543 | -$17,653 |
| % Margin | – | – | – | – |